Startups & Launch
Strategy & Execution.
subrosa is Built and Designed to Support Global Commercialization of Biotech Startups
XCLR8ED Access to Markets, KOLs, HCPs, Patients, Talents and Capital. Globally
A substantial number of drugs for innovative therapies are being developed both in the US and, increasingly, abroad—primarily in China, the APAC region, and Europe. A dynamic growing landscape of startups faces pricing and policy pressures, including the continued implications of Most Favored Nation (MFN) frameworks, which are converging with rapid advancements in data, AI, and evolving distribution models.
These challenges and opportunities are why we established subrosa Health & Capital nine years ago, to create a global solutions ecosystem that spans the entire product lifecycle and patient journey.
as time is crucial in startup and launch situations, we help rare disease and biotech headquarters with their core needs: to support fundraising, optimize & execute the most effective global medical & commercial launch strategy, to recruit patients years earlier than today’s standards, secure their treatment & adherence and supply them even if the drug is not authorized in a market. Measurable impact right when and where it matters most, for long-term win-win partnerships.
Most startups are under-resourced when it comes to rapidly establishing a robust operational foundation. Our platforms bridge your organizational and expertise gaps as long as you need it, empowering you to concentrate on the launch and move at XCLR8ED speed, from the clinic to market entry to lifecycle management—while minimizing financial risks. Worldwide.
Built for Speed
Startups, Launch Strategy & Execution
Originator’s HQ
we bridge your gaps
own Medical & Commercial Structure, Team Building, Launch & Lifecycle Management.
EAP-Regulatory Strategy, Project Planning, Implementation, KOL-Engagemt, Patient identification
Assessment & Contracting Licensing / Distribution partner Alliance-Management
axxessive is the strategic partner for startups and companies planning to take their first steps outside of their home market.
subrosa Capital supports early startups with CXO-services and fundraising. subrosa OmicsAI evaluates, validates and publishes the real market size in case of genetic-based rare disease.
Explore “How rare is it?”Between Phase I and Phase II trials, it’s the right time to plan study strategy and patient recruitments (subrosa OmicsAI) and to define the global go-to-market strategy—covering your asset’s potential value, launch sequencing, pricing, resource & P&L-planning, and Board-ready GTM scenarios across the three primary commercialization pathways: Core markets, EAP markets and Partnering markets. axxessive can guide you through each of them.
subrosa Group’s distinctive strength lies in our capacity to execute all three scenarios to-the-end, fully integrated from one source to bridge your gaps and fast-track your launch.
What we do for (non-Orphan) Startup companies*
Go-to-Market, Launch & Talent
Commercial Deployment & HR Operations
Patient Access & Treatment
Capital, Funding & Partnering
* Disclaimer: We work hard to roll-out our services across the globe. Nevertheless not every solution is available in all 45 covered markets
Built for speed
We don’t promise what we might not be able to keep.